CAJ | 학술논문

目的：系统评价白芍总苷（TGP）辅助治疗过敏性紫癜（HSP）的临床疗效及安全性。方法计算机检索 Pubmed、EMbase、Cochrane 图书馆、中国知网、维普数据、万方数据及美国ClinicalTrials.gov网站，收集所有关于TGP治疗HSP的随机对照试验（RCT）。按Cochrane系统评价的方法评价纳入研究的质量，并提取有效数据，采用RevMan 5.2软件进行Meta分析。结果最终共纳入4个RCT，包括247例患者。Meta分析结果显示：4篇文献在治疗14 d后观察临床疗效， TGP辅助治疗组的疗效优于对照组，治愈率OR=2.66，95%CI（1.51，4.67），P=0.0007；有效率OR=3.29，95% CI（1.49，7.27），P=0.003；3篇文献评价了患者症状缓解的情况，治疗组皮疹消退的时间明显短于对照组[MD=－2.05，95% CI（－3.33，－0.77），P=0.002]；安全性方面，治疗组与对照组均未出现严重不良反应，且两组无统计学差异。结论 TGP辅助治疗HSP的疗效较好，能缓解患者的症状，缩短症状改善的时间，减少复发率，且不良反应发生率低，患者耐受性好。
목적：계통평개백작총감（TGP）보조치료과민성자전（HSP）적림상료효급안전성。방법계산궤검색 Pubmed、EMbase、Cochrane 도서관、중국지망、유보수거、만방수거급미국ClinicalTrials.gov망참，수집소유관우TGP치료HSP적수궤대조시험（RCT）。안Cochrane계통평개적방법평개납입연구적질량，병제취유효수거，채용RevMan 5.2연건진행Meta분석。결과최종공납입4개RCT，포괄247례환자。Meta분석결과현시：4편문헌재치료14 d후관찰림상료효， TGP보조치료조적료효우우대조조，치유솔OR=2.66，95%CI（1.51，4.67），P=0.0007；유효솔OR=3.29，95% CI（1.49，7.27），P=0.003；3편문헌평개료환자증상완해적정황，치료조피진소퇴적시간명현단우대조조[MD=－2.05，95% CI（－3.33，－0.77），P=0.002]；안전성방면，치료조여대조조균미출현엄중불량반응，차량조무통계학차이。결론 TGP보조치료HSP적료효교호，능완해환자적증상，축단증상개선적시간，감소복발솔，차불량반응발생솔저，환자내수성호。
ObjectiveTo evaluate the efficacy and safety of total glucosides of paeony (TGP) for Henoch-Schonlein purpura (HSP).Methods Clinical randomized controlled trials (RCTs) were identified by searching Pubmed, EMbase, Cochrane library, CNKI, VIP, WANFANG Med online and ClinicalTrial.gov web site. The quality of included studies was assessed according to the criteria recommended Cochrane Collaboration. Meta-analysis was performed on RevMan 5.2 software.Results Four trials (n=247) were included. The results of Meta-analysis demonstrated that, four trials evaluated the efficiency of TGP adjuvant therapy for HSP was marked, the curative ratio odds ratio (OR)=2.66, 95% confidence interval (CI) (1.51, 4.67),P=0.000 7; the effective ratioOR=3.29, 95%CI (1.49, 7.27), P=0.003; 3 trials reported symptom remission after treatment for 14 days, the time of deflorescence shortened in TGP group, mean difference (MD)=-2.05, 95%CI (-3.33,-0.77), P=0.002; there were no serious adverse effects happened in both groups, and the difference between two groups was not significant in statistics as well.Conclusion Compared with routine treatment, TGP adjuvant therapy might be a better choice for HSP with more remarkable efficacy and few adverse effects.